TXMD TherapeuticsMD Quarterly EPS earnings growth

Public company logo of therapeuticsmd.com (TXMD)

TherapeuticsMD, Inc. (TXMD) aims for dominance in the menopause therapy segment through direct sales and pharmacy chains. The quarterly EPS change metric on GURU.Markets confirms this trajectory, where 222.50 determines this parameter level. A stable staff of ethical specialists and high loyalty among gynecologists toward licensed products create a reliable foundation for further growth in business value.

TherapeuticsMD Inc (TXMD) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/17/2026

therapeuticsmd.com (TXMD) - metric breakdowns and financial figures

- market value and analyst target forecast:
Comprehensive company analysis:TherapeuticsMD, Inc.
Flagship merchandise of TherapeuticsMD, Inc.

This indicator measures the rate of change in earnings per share, demonstrating the actual efficiency of capital generation for the reporting quarter. Analyzing the quarterly EPS growth profile allows for an assessment of the business sustainability of TherapeuticsMD, Inc. (TXMD), where financial results depend directly on the market share of women's health drugs and the successful commercialization of intellectual property in reproductive medicine.